An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib is approved in the United States for use in adults with moderately to severely active RA and an inadequate response or intolerance to methotrexate. OBJECTIVES: To (a) evaluate, using...

Descripción completa

Detalles Bibliográficos
Autores principales: Claxton, Lindsay, Jenks, Michelle, Taylor, Matthew, Wallenstein, Gene, Mendelsohn, Alan M., Bourret, Jeffrey A., Singh, Amitabh, Moynagh, Dermot, Gerber, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398082/
https://www.ncbi.nlm.nih.gov/pubmed/27579831
http://dx.doi.org/10.18553/jmcp.2016.22.9.1088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398082/
https://www.ncbi.nlm.nih.gov/pubmed/27579831
http://dx.doi.org/10.18553/jmcp.2016.22.9.1088

Ejemplares similares